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Summary Tumour markers now have an established role in tumour diagnosis and patient management.
However, antibodies used to detect these tumour markers have in some instances proved unreliable, with a
low rate of sensitivity and specificity. In this study we wished to evaluate the role of a commercial antibody
to myoglobin as a marker of rhabdomyosarcomas. The purpose of this investigation was to assess the
sensitivity and specificity of myoglobin antiserum as a marker of rhabdomyosarcomas. This was performed by
reacting a large number of tumours (sarcomas, carcinomas and melanomas) with a polyclonal anti human
myoglobin antiserum. Staining was demonstrated in 60% of rhabdomyosarcomas. Only two tumours from a
total of 226 non-skeletal muscle tumours showed a positive reaction (0.88%). One was a leiomyosarcoma and
the other had been classified as an undifferentiated sarcoma but a rhabdomyosarcoma was included in its
differential diagnosis. It is of interest that both had been earlier irradiated. This antiserum was therefore a
specific but not a very sensitive tumour marker. Its rate of staining of rhabdomyosarcomas is compared with
the results in the literature. A great disparity is found and the reasons for this are discussed.
A tumour marker is a tumour derived or associated product
the detection of which indicates the presence of a specific
line of differentiation in a tumour. Any antigenic deter-
minant specific to a cell type may be used as a tumour
marker. These may include hormones, enzymes, intermediate
filaments, proteins, etc. Their presence is identified by the
use of antibodies raised against an antigenic determinant in
or on the tumour cell.
Tumour markers now have an established role in clinical
practice as aids in the detection of primary or recurrent
tumour, in tumour treatment (by targetting the antibody
with a cytotoxic drug) and in screening for certain malignan-
cies. Since the advent of immunocytochemical techniques
which permit the detection of tumour markers in formalin
fixed material, the histopathologist has discovered that many
of these markers are valuable additional diagnostic tools.
However, it is essential that the antibodies used to detect
them are specific and sensitive for the tumour in question. It
is therefore essential that these antibodies are rigorously
tested on a large group of tumours under controlled con-
ditions such as in this study.
Rhabdomyosarcomas account for 19% of the sarcomas
seen in a pathology department (Russel et al., 1977). The
morphological appearances of these tumours can be variable
and their histopathological diagnosis is sometimes difficult,
especially in the absence of cross striations. Diagnosis is then
based either on immunocytochemical staining for a specific
tumour marker or on electron microscopy. As the latter is
expensive and time-consuming and requires the availability
of an electron microscope, these tumours are generally first
subjected to immunocytochemical analysis. The expression of
myoglobin by these sarcomas is therefore regarded as a
useful diagnostic marker (Corson & Pinkus, 1981; Kindblom
et al., 1982; Brooks, 1982). However, many different com-
mercial myoglobin antisera are available for this purpose
and their reported rates of reactivity show great variability.
In this study we report the reactivity of a commercially
available antibody to myoglobin (Dakopatts) on a large
series of sarcomas. From these results we assess the useful-
ness of this antibody as a marker of rhabdomyosarcomas
and compare its performance to other commercially available
antibodies to myoglobin.
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Materials and methods
One hundred and eighty-three soft tissue sarcomas including
25 rhabdomyosarcomas, 41 carcinomas and 27 malignant
melanomas were included in the study (Table I). The sarco-
mas were taken from the files of the Histopathology Depart-
ment of the Westminster Medical School and Hospital and
form part of a large study which examined the immunocyto-
chemical profile of different types of soft tissue sarcomas
(Leader et al., 1986a,b,c, 1987a,b,c,d). They represent some
of the sarcomas seen over a 20-year period in this institution.
Only tumours with available blocks were used in this study.
All had been formalin fixed and paraffin embedded. All
sarcomas had been diagnosed by MacKenzie (1970), an
acknowledged authority in soft tissue tumour diagnosis. His
criteria for the diagnosis of sarcomas, including rhabdomyo-
sarcomas, were similar to those of Enzinger & Weiss (1983).
The subtypes of rhabdomyosarcomas included in the study
are shown in Table II. Cross striations were not essential for
a histopathological diagnosis of rhabdomyosarcoma. A
representative section from each tumour was reacted with
commercially available polyclonal rabbit anit human myo-
globin obtained from Dakopatts. The peroxidase anti peroxi-
dase (PAP) method was used (details available on request).
Anti human myoglobin antiserum was used at a dilution of
1:200 for 60min on pre-trypsinised (0.1% trypsin for 30min)
sections. Sections were reacted in batches of 20-30. Each
batch included appropriate controls.
Each section was examined without knowledge of the H
and E diagnosis and the results were tabulated. A positive
result was interpreted as discrete granular cytoplasmic stain-
ing in tumour cells. Necrotic cells were disregarded in this
evaluation.
Results
The results are summarised in Table I and those of the
rhabdomyosarcomas are shown in more detail in Table II.
Tumour cells in 15 of the 25 rhabdomyosarcomas stained
(Figure 1) and two results were equivocal. All the main
subtypes of rhabdomyosarcomas were represented amongst
the positive cases (5/7 alveolar, 7/11 embryonal, 3/5 pleo-
morphic). Staining in all cases was granular and restricted to
the cytoplasm; membrane staining was not particularly
intense. Cross striations were highlighted by the staining.
The number of positively staining cells in each tumour
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Table I Anti-myoglobin staining of sarcomas, carcinomas and
melanomas
Tumours
Rhabdomyosarcomas
Leiomyosarcomas
Synovial sarcomas
Angiosarcomas
Clear cell sarcomas
Neurofibrosarcomas
Epithelioid sarcomas
Liposarcomas
Malignant haemangiopericytomas
Malignant fibrous histiocytomas
Fibrosarcomas
Sarcomas unclassified
Carcinomas
Oat cell carcinomas
Melanomas
No. + ve -ve Equivocal
25
21
19
6
5
17
7
23
14
23
18
5
31
10
27
15
1
0
0
0
0
0
0
0
0
0 1
0
0
0
8
20
19
6
5
17
7
23
14
23
18
4
31
10
27
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
varied considerably, among the different cases. When the
positively staining cells were few in number, the positive cells
were randomly located rather than being arranged in clumps.
The intensity of staining also varied from case to case but it
has been our experience that intensity of immunocyto-
chemical staining can vary with room temperature and with
different batches of antisera and diaminobenzidine. Surpris-
ingly, well differentiated rhabdomyoblasts with cross stril-
tions failed to stain in four instances. Conversely two
pleomorphic rhabdomyosarcomas in which cross striations
could not be found at light microscopy stained with anti-
myoglobin. It is evident from this study that by using either
the presence of cross striations or reactivity with Dakopatts
myoglobin antisera as criteria for the diagnosis of
rhabdomyosarcomas, the diagnosis of these tumours can bc
confirmed in an increased number of cases (see Table II).
There were only two positive reactions amongst the 183 non-
rhabdomyosarcomatous sarcomas, a leiomyosarcoma and an
undifferentiated sarcoma (Figures 2 and 3). The leiomyo-
sarcoma was a spindle cell tumour with eosinophilic cyto-
plasm and myofilaments were identified on PTAH staining.
No cross striations were evident. Staining for desmin was
positive. The undifferentiated sarcoma was a high grade
sarcoma with no differentiating features morphologically.
However, staining for desmin (in a retrospective study) was
positive, supporting a diagnosis of a tumour showing muscle
differentiation. Faint, cytoplasmic staining was also seen in
squamous epithelium, in neutrophils, in bronchial epithe-
lium, in the mucus of salivary glands and in the endothelial
lining of some blood vessels in tissue invaded by the
rhabdomyosarcomas. However, no staining was seen in
either the carcinomas or melanomas.
Discussion
Myoglobin is a heme protein with a molecular weight of
17,800 daltons which is found exclusively in striated muscle.
Immunohistochemistry shows its localisation in regions near
the sarcolemmal membrane. As its concentration varies with
fibre type, immunohistochemical staining of normal muscle
shows a chequerboard pattern. Caution is required in the
histopathological interpretation of myoglobin staining. Posi-
tively staining residual myocytes in tissue sections must not
be misinterpreted as tumour cells. Reactive histiocytes and
even carcinomas, lymphomas and malignant melanomas
when infiltrating skeletal muscle may show a positive re-
action for myoglobin (Eusebi et al., 1984). It is suggested by
the authors that myoglobin may be transferred from skeletal
muscle to the infiltrating tumour cells.
The results of this study using antiserum from Dakopatts
show that only 60% of rhabdomyosarcomas stained (Table
l). So as to exclude the possibility of incorrect diagnosis, the
original histopathological diagnosis of the rhabdomyo-
sarcomas in this study was reviewed. In each the diagnosis
was confirmed. All negatively staining rhabdomyosarcomas
were restained using similar trypsinisation to the initial study
and a similar dilution of primary antisera. No additional
staining was seen. Seven papers have examined the staining
reactions of anti human myoglobin antisera with
rhabdomyosarcomas (Table III) (Corson & Pinkus, 1981;
Brooks, 1982; Kindblom et al., 1982; Tsokos et al., 1983;
Kahn et al., 1983; Kagawa et al., 1983; de Jong et al., 1984).
The results in three of the seven suggest that myoglobin is a
useful marker of skeletal muscle differentiation (Corson &
Pinkus, 1981; Brooks, 1982; Kindblom et al., 1982). How-
ever, three papers report positive staining only in 47, 36 and
50% of rhabdomyosarcomas (de Jong et al., 1983; Kahn et
Table II Anti-myoglobin staining of rhabdomyosarcomas
Cross
Age Site striations Type Anti-myoglobin
3 Lymph node + embryonal +
44 Buttock + embryonal
10 Lymph node - embryonal
10 Jaw + embryonal +
2 ? + embryonal
15 Paratesticular + embryonal +
15 Mouth + embryonal
3 Bladder + embryonal +
27 Nose + embryonal +
19 Ear + embryonal +
16 Paratesticular + embryonal +
26 Leg - alveolar +
14 Arm - alveolar
32 Thigh + alveolar
? ? - alveolar +
24 Palate + alveolar +
24 Leg - alveolar +
25 Hand + alveolar +
85 Arm + pleomorphic E
84 Leg + pleomorphic +
? Thigh - pleomorphic +
66 Mouth pleomorphic
28 Thigh - pleomorphic +
23 Thigh + mixed E
14 Thigh - mixed
E =equivocal.108 M. LEADER et al.
Figure 1 A rhabdomyosarcoma showing undifferentiated small
round tumour cells and also some well-differentiated rhabdomyo-
blasts. The latter (arrows) have stained with the myoglobin
antisera. Anti-myoglobin x 400.
Figure 2 A leiomyosarcoma that stained with anti-myoglobin.
The tumour is formed by spindle and ovoid cells arranged in
fascicles. There is no evidence of cross striations or of strap
shaped cells. H and E x400.
al., 1983; Kagawa et al., 1983) respectively. In another study
it was found to be a useful marker of alveolar but not of
embryonal rhabdomyosarcomas; no pleomorphic
rhabdomyosarcomas were included in the study (Tsokos et
al., 1983).
This review of the literature showing reported rates of
positive staining ranging from 100 to 36% in different series
(Table III) highlights the disparity in the documented stain-
ing reactions of rhabdomyosarcomas and myoglobin anti-
serum. The most likely reason for this disparity is the
differing source of antibody. It is noteworthy that 3/5 studies
using antiserum from Cappel Laboratories attained a high
rate of reactivity (76, 88 and 100%). Other possible causes
for the disparity include variability of fixation of tissues and
possibly a difference in enzyme digestion of tissue sections
but the reports do not include sufficient details to confirm
this. With regard to the positive reactions in the leiomyo-
sarcoma and unclassified sarcoma in this study, it was of
interest that both tumours had been earlier treated by
radiotherapy. It has been previously suggested that radio-
Figure 3 An undifferentiated sarcoma that stained with anti-
myoglobin. The tumour is formed by ovoid and round cells with
vesicular nuclei and prominent nucleoli. Some cells had tapering
cytoplasm (arrow) suggestive of strap cells but no cross striations
were identified. A heavy polymorphic infiltrate was seen focally
in the tumour, as shown here, but was absent in other areas. The
differential diagnosis included a malignant inflammatory fibrous
histiocytoma and a rhabdomyosarcoma. H and E x400.
therapy may give misleading results with immunocyto-
chemical tumour markers (Leader et al., 1986b, 1987a). The
reason for this is unclear; it may be that the cells 'mop up'
the primary antibody non-specifically. This is suggested by
positivity in irradiated viable skeletal muscle using anti
factor VIII related antigen in an earlier study (Leader,
1986b). It may also be related in some instances to the
induction of a new line of differentiation by radiotherapy.
The undifferentiated tumour can almost certainly be re-
classified as a rhabdomyosarcoma in view of its positivity for
myoglobin and desmin and therefore it can be regarded as a
genuine positive reaction. Therefore in this study there was
only one positive tumour among 225 non-rhabdomyo-
sarcomatous tumours.
A number of studies have also investigated the value of
other markers such as myosin (Tsokos et al., 1983), creati-
nine kinase (Tsokos et al., 1983), creatinine kinase MM
(Tsokos et al., 1983; Kahn et al., 1983), calsequestrin and
calcium magnesium-dependent ATPase of sarcoplasmic reti-
culum (Kahn et al., 1983) and desmin (Kahn et al., 1983;
Leader et al., 1987a; Kias et al., 1987) in the diagnosis of
rhabdomyosarcomas. The first three of these appear to be
more sensitive indicators of skeletal muscle differentiation
than myoglobin; however, they are associated with a signifi-
cant false positive reaction rate among carcinomas (approxi-
mating 30%) and therefore their discriminatory value is
limited. Desmin, ATPase and calsequestrin were found in a
higher percentage of rhabdomyosarcomas than myoglobin,
but the specificity of only desmin has been investigated and
this in only one study (Leader et al., 1987a).
Tumour markers have a useful role in diagnostic surgical
pathology. Positive staining must be carefully interpreted
and a positive result accepted only when the tumour cells are
viable, not adjacent to foci of tumour necrosis and when the
staining is discrete, granular and confined to or within the
cell. When one uses these criteria for a positive reaction and
when one uses appropriate positive and negative controls,
positivity in a cell reflects the presence within the cell of an
epitope to which the antibody has been raised. This result
therefore can be used to indicate that the tumour cell shows
a specific line of differentiation when the epitope being
recognised is specific. Of course it must be borne in mind
that, with polyclonal antisera in particular, cross reactivity
may be found with other types of tumours due to the variety
of possible epitopes recognised by this type of antiserum.MYOGLOBIN AS RHABDOMYOSARCOMA MARKER 109
Table III Other reports of anti-myoglobin staining in rhabdomyosarcomas
Antibody Cross
Tumours No. +ve -ve source striations Authors
Alveolar 7 5 2 Cappel 1 Corson & Pinkus (1981)
Embryonal 5 5 0 3
Pleomorphic 5 3 2 1
Alveolar 3 3 0 Cappel n.k. Brooks (1982)
Embryonal 15 12 3
Pleomorphic 9 9 0
Alveolar 9 9 0 Cappel n.k. Kindblom et al. (1983)
Embryonal 9 9 0 n.k.
Alveolar 8 4 4 Cappel n.k. de Jong et al. (1984)
Embryonal 12 5 7
Pleomorphic 3 2 1
Alveolar 11 10 1 Cappel n.k. Tsokos et al. (1983)
Embryonal 11 5 6
Alveolar 12 8 4 Behring n.k. Kahn et al. (1983)
Embryonal 53 16 37
Alveolar 12 4 8 Miles-Yede 1 Kagawa et al. (1983)
Embryonal 9 6 3 3
Pleomorphic 5 3 2 4
n.k.=not known.
The pathologist should also be aware that radiotherapy may
give misleading results on antibody staining as already
outlined.
In conclusion this paper demonstrates that antimyoglobin
is a specific marker of rhabdomyosarcomas, showing positive
reactivity in only 0.4% of non-rhabdomyosarcomatous sar-
comas. However, its sensitivity as a tumour marker is
variable, being dependent at least on the source of the
antibody. Before the histopathologist places too much
emphasis on the results obtained with tumour markers it is
essential that their sensitivity and specificity are known from
investigations such as this.
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